XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib

BACKGROUND: PARP inhibitor (PARPi) monotherapy is a new strategy in BRCA germ-line deficient triple negative breast cancer (TNBC). However, not all patients respond, and the development of resistance limits the use of PARPi monotherapy. Therefore, the development of alternative synthetic lethality s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Ali, Reem, Alblihy, Adel, Toss, Michael S., Algethami, Mashael, Al Sunni, Rabab, Green, Andrew R., Rakha, Emad A., Madhusudan, Srinivasan
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7758562/
https://ncbi.nlm.nih.gov/pubmed/33425022
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920974201
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados